July 24, 2017
Wellesley, Mass., Jul 24, 2017 – Continuing medical research and advances are supporting a steady growth in the sale of the building block laboratory items needed in biotechnology. The estimated $3.6 billion biologics industry is expected to see a 5% annual growth in sales through 2021, according to a new report by BCC Research, Global Markets for Media, Sera and Reagents in Biotechnology.
Cells grown in a controlled environment use a combination of media, sera and reagents. This latest study by BCC Research found that competition, R&D and patent expirations are among the market forces affecting industry leaders, GE Healthcare Life Sciences, Corning, Merck KGaA, ThermoFisher Scientific, Lonza Corp. and others. Emerging markets outside the U.S. and Europe are anticipated to grow at a compound annual growth rate (CAGR) of 6.5% from 2016 to 2022.
"Global reach, on the one hand, and regulatory frameworks on the other make this a field an important test of speed and safety. The European Medicines Agency (EMA) and the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) all have guidelines as industry standards,” says Robert Hunter, senior healthcare editor at BCC Research. “New cell lines, products proteins and antibodies are being developed at a rapid pace.”
Editors and reporters who wish to speak with the analyst should contact Steven Cumming at firstname.lastname@example.org.
Global Markets for Media, Sera and Reagents in Biotechnology( BIO014J )
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email email@example.com or visit www.bccresearch.com/media to request access to our library of market research.